SCHEMBL14924029

SCHEMBL14924029

COP(=O)(Cc1ccc(C(C)C)cc1)OC

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IDO1 P14902 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
RAB9A P51151 4/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
NPC1 O15118 3/20 0.42
ALDH1A1 P00352 1/20 0.42
PGK1 P00558 3/20 0.39
PGK2 P07205 3/20 0.39
RXRA P19793 1/20 0.38
RXRB P28702 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
HPGD P15428 1/20 0.38
TYR P14679 1/20 0.36
S1PR1 P21453 1/20 0.36
S1PR3 Q99500 1/20 0.36
NFE2L2 Q16236 1/20 0.36
KDM4E B2RXH2 1/20 0.36
POLB P06746 1/20 0.36
PYCR1 P32322 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2037665 0.85 KLK8 (0.36) SMN1; SMN2PGK1PGK2MEN1KMT2A
SCHEMBL24549419 0.84 ALDH1A1 (0.41) L3MBTL1RAB9ASMN1; SMN2NPC1ALDH1A1
SCHEMBL5410661 0.81 IDO1 (0.43) IDO1L3MBTL1RAB9ASMN1; SMN2NPC1
SCHEMBL15060697 0.81 PGK1 (0.34) L3MBTL1PGK1PGK2
SCHEMBL5870639 0.80 ALDH1A1 (0.40) IDO1L3MBTL1RAB9AALDH1A1MEN1
SCHEMBL914693 0.80 FDPS (0.41) ALDH1A1MEN1KMT2A
SCHEMBL7043203 0.79 PTK2 (0.39) RAB9ASMN1; SMN2NPC1ALDH1A1MEN1
SCHEMBL13026508 0.79 ACHE (0.43) L3MBTL1RAB9ANPC1PGK1PGK2
SCHEMBL913793 0.78 FDPS (0.40) ALDH1A1
SCHEMBL12016977 0.78 IDO1 (0.45) IDO1L3MBTL1RAB9ASMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-RE46511-E1 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2017-08-15 US disclosed
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2016-08-11 US disclosed
US-9345719-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD. (KR) 2016-05-24 US disclosed
US-8957065-B2 Fused pyrimidine derivatives for inhibition of tyrosine kinase activity HANMI SCIENCE CO., LTD (KR) 2015-02-17 US disclosed
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD (KR) 2015-02-12 US disclosed
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY HANMI SCIENCE CO., LTD. (KR) 2013-05-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229868-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, LTK, FYN IDO1 1851/4885L3MBTL1 2596/4885RAB9A 1938/4885
US-20150045324-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 IDO1 1511/4885L3MBTL1 2790/4885RAB9A 2172/4885
US-20130116213-A1 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITY LCK, FYN, TYK2 IDO1 1511/4885L3MBTL1 2790/4885RAB9A 2172/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.